Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.
Sanofi and Regeneron have rolled out promising Phase III data on their cholesterol drug alirocumab, which handily breezed by Merck's Zetia in lowering bad LDL cholesterol. The partners are in a high-stakes race to win the first regulatory approval for a PCSK9 inhibitor.
Being an R&D chief at a major biopharma company in today's environment of major research cutbacks, patent expirations and pressure from investors to speed new drugs to market is no easy...
After partners Regeneron and Sanofi announced more than 10 late-stage studies last year, Regeneron revealed plans Tuesday to take a shot at a trial to test less frequent dosing of the experimental therapy.
With a new blockbuster drug and more potential hits in development, Regeneron Pharmaceuticals has been successful long enough for top executives to consider the challenges of keeping the entrepreneurial culture behind the R&D streak alive. Read more >>
Dr. George Yancopoulos is the highest paid biopharma executive in the world. In interviews with company leaders at Regeneron, FierceBiotech has learned more about why the company rewarded its chief scientist with a pay package of $81.6 million. Read more >>
With one likely blockbuster on the market in Eylea and at least three others in development, Regeneron Chief Scientific Officer Dr. George Yancopoulos has plenty to keep him busy for the next several years. Read the full feature >>
It's a great time to helm a large biotech company, generally. Big biotech players overall posted major growth last year, and their CEOs got richer in the process. Most got fat raises while others saw their bundles of pay pale in comparison to 2011 figures. We surveyed the total compensation packages of the 10 largest biotech companies based on market capitalization as of early May, sleuthing mostly proxy statements for the financial details on pay for some of the most powerful people in the industry. Check it out >>
Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi for full rights to the pair of antibody programs for use against eye diseases.
Regeneron Pharmaceuticals has rolled out plans to add about 400 new workers to its fast-growing staff after it builds two new facilities, adding 300,000 square feet of lab and office space to its sprawling campus in New York state.